Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06380348
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-23
First Post:
2024-04-09
Brief Title:
JMT101 in Combination With Osimertinib Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer NSCLC Characterized by Epithermal Growth Factor Receptor EGFR Exon 20ins Mutations
Sponsor:
Shanghai JMT-Bio Inc
Organization:
Shanghai JMT-Bio Inc
Organization Data
Organization:
Shanghai JMT-Bio Inc
Class:
INDUSTRY
Study ID:
JMT101-012
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai JMT-Bio Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None